StreetAlpha.app
Home › Stocks › BCRX

Biocryst Pharmaceuticals Inc (BCRX)

Healthcare
$7.22
▼ −1.37%
LAST CLOSE · NOV 20

BioCryst Pharmaceuticals develops and sells medicines for hereditary angioedema and other rare diseases. It last closed at $7.22 on Nov 20, down 1.37% on the day. The next earnings report for BCRX is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, BCRX reported EPS of $0.14 on revenue of $180.3M, with revenue up 13.1% from a year ago. Over its last 8 reports the stock moved an average of 7.3% the session after earnings. Over the last 12 months BCRX insiders bought $0 of stock on the open market and sold $4.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is BCRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BCRX.

Key Stats

Last 12 months
Results
Revenue
$961.5M
+60.3% vs a year ago
Net income
−$359.7M
−37.4% margin
EPS (diluted)
−$1.28
Free cash flow
$365.8M
38.0% margin
Valuation
Market cap
$1.9B
257.3M shares
P/E
–
No P/E while losing money
Price to sales
1.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$97.0M
At Sep 30
Debt
$395.6M
At Sep 30
Shareholder equity
−$397.4M
Shares outstanding
257.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $157.2M$157.2MFY2021FY2022: $270.8M$270.8MFY2022FY2023: $331.4M$331.4MFY2023FY2024: $450.7M$450.7MFY2024FY2025: $874.8M$874.8MFY2025

From BCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
$0.14
Quarter ended Sep 2026
Year ago EPS
$0.06
+133.3% on a GAAP basis
Revenue
$180.3M
+13.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.13Dec '24Mar 2025: $0.00Mar '25Jun 2025: $0.02Jun '25Sep 2025: $0.06Sep '25Dec 2025: $1.13Dec '25Mar 2026: -$2.98Mar '26Jun 2026: $0.30Jun '26Sep 2026: $0.14Sep '26Latest $0.14
Revenue by quarter
Dec 2024: $131.5MDec '24Mar 2025: $145.5MMar '25Jun 2025: $163.4MJun '25Sep 2025: $159.4MSep '25Dec 2025: $406.6MDec '25Mar 2026: $156.4MMar '26Jun 2026: $218.3MJun '26Sep 2026: $180.3MSep '26Latest $180.3M
How BCRX moved after its last 8 reports
Average move the session after a report ±7.3%
Nov 4, 2026Time not announced−3.9%
Aug 5, 2026Time not announced+0.6%
May 6, 2026Time not announced−2.2%
Feb 26, 2026Time not announced+4.6%
Jan 12, 2026After the close−4.8%
Oct 14, 2025Time not announced−8.8%
Aug 4, 2025Time not announced+9.8%
May 5, 2025Time not announced+23.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BCRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BCRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BCRX

Technical Analysis

BCRX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 8% below its 20 day and 12% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $7.11, and the nearest resistance the Pivot at $7.25.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 4.4%/day
Key levels
$11.2252 week high+55.4%
$8.87100 day average+22.9%
$8.82200 day average+22.2%
$8.0850 day average+11.9%
$7.8320 day average+8.4%
$7.78Swing high (Nov 12)+7.8%
$7.36Pivot R1+1.9%
$7.25Pivot+0.4%
$7.22Last close
$7.11Pivot S1−1.5%
$6.2352 week low−13.7%
Indicators
RSI (14)34.75Weak, oversold below 30Neutral
MACD-0.25Below its signal lineBearish
Stochastic4.3Near the bottom of its rangeOversold
ADX (14)14.9No clear trend
Williams %R-95.6Oversold below −80, overbought above −20Oversold
CCI (20)-108.3Oversold below −100, overbought above 100Oversold
Rate of change−6.1%Change over 10 sessionsBearish
ATR (14)$0.32Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BCRX

What happened before

See how BCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BCRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BCRXHow many large options trades hit BCRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BCRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●150 buying vs 164 selling
  • ▼Held by funds -7.7 pts
  • ▲Funds holding +15
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding334319+4.7%
In funds' top 1010–
Held by funds94.8%102.5%−7.7 pts
New / increased52 / 9853 / 132−18.9%
Reduced / sold out126 / 3886 / 38+32.3%
Put/call ratio0.000.01−90.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BCRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BCRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.1M7 sales · 3 insiders
85% of the selling was under pre-arranged trading plans.
2025-12 sold $1.5M2026-03 sold $1.9M2026-05 sold $697KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 18Amy E McKeeDirectorSale11,180$8.97$100K
May 13Alane P BarnesChief Legal OfficerSale plan62,500$9.54$596K
Mar 20Theresa HeggieDirectorSale49,933$10.11$505K
Mar 16Alane P BarnesChief Legal OfficerSale plan150,000$9.15$1.4M
Dec 22, 2025Alane P BarnesChief Legal OfficerSale plan21,773$7.65$167K
Dec 15, 2025Alane P BarnesChief Legal OfficerSale plan21,210$7.65$162K
Every insider buy and sale for BCRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BCRX insider trades →

From SEC Form 4 filings by BCRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCRX is in one of them and how their past BCRX trades turned out.

BCRX in the AI portfolios
Loading…

BCRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BCRX in an article yet. Here's the latest on the wider market.

BCRX in the news

BCRX Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
1
Last filed Sep 4
Who traded BCRX · since 2022
Latest 5 filings
$1K – $15KTraded Jul 10, 2026Filed Sep 4, 2026
$1K – $15KTraded Nov 13, 2025Filed Dec 15, 2025
$1K – $15KTraded Oct 16, 2023Filed Nov 11, 2023
$1K – $15KTraded Sep 15, 2023Filed Oct 15, 2023
$1K – $15KTraded Aug 11, 2022Filed Sep 16, 2022
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KJul 10, 2026Sep 4, 202656 d
Gilbert CisnerosD · CABuy$1K – $15KNov 13, 2025Dec 15, 202532 d
Josh GottheimerD · NJBuy$1K – $15KOct 16, 2023Nov 11, 202326 d
Josh GottheimerD · NJSell$1K – $15KSep 15, 2023Oct 15, 202330 d
Josh GottheimerD · NJBuy$1K – $15KAug 11, 2022Sep 16, 202236 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Biocryst Pharmaceuticals

BioCryst Pharmaceuticals is a biotechnology company based in Durham, North Carolina. It develops and sells medicines for hereditary angioedema and other rare diseases. Its main product, ORLADEYO, is an oral medicine taken once daily to prevent attacks of hereditary angioedema, and it is approved in the United States and several other markets. The company also has RAPIVAB, an intravenous treatment for influenza, approved in several countries. Its customers include patients with these conditions, along with the healthcare providers and insurers who support their care.

Headquarters
Durham, NC
Founded
1986